Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin ‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

ConclusionsThe recommendations provided in this document are intended to assist the clinician in optimizing vancomycin for the treatment of invasive MRSA infections in adult and pediatric patients. An AUC/MIC by broth microdilution (BMD) ratio of 400 to 600 (assuming MICBMD of 1 mg/L) should be advocated as the target to achieve clinical efficacy while improving patient safety for patients with serious MRSA infections. In such cases, AUC ‐guided dosing and monitoring is the most accurate and optimal way to manage vancomycin therapy.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - March 31, 2020 Category: Drugs & Pharmacology Authors: Michael J. Rybak, Jennifer Le, Thomas P. Lodise, Donald P. Levine, John S. Bradley, Catherine Liu, Bruce A. Mueller, Manjunath P. Pai, Annie Wong ‐Beringer, John C. Rotschafer, Keith A. Rodvold, Holly D. Maples, Benjamin M. Lomaestro Tags: Special Article Source Type: research